Acute ischemic stroke (AIS) occurs due to blockage of blood supply to the brain, often caused by clot or thrombus formation. AIS treatments include thrombosis and thrombolytic therapies to dissolve blood clots and restore blood flow. Additionally, neuroprotective agents help minimize brain damage. Advancements in AIS management include drugs with extended time windows, bioabsorbable stents, and stem cell therapies.

The global Acute Ischemic Stroke (AIS) Market is estimated to be valued at US$ 9.2 billion in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends: Advancements in treatment options have accelerated the growth of the AIS market. Extended time windows for thrombolysis allow more patients to be treated compared to previous narrow time windows. For instance, tenecteplase was approved for use up to 9 hours from symptom onset compared to previous 4.5-hour limit with alteplase. Additionally, bioabsorbable stents can be used for emergent large vessel occlusion and dissolve away after vessel recanalization, reducing complications. Stem cell therapies also show promise, as ongoing clinical trials evaluate the ability of mesenchymal stem cells to reduce infarction size and promote recovery after AIS. These expanding treatment opportunities have increased the market for AIS management.

Segment Analysis
The global Acute Ischemic Stroke (AIS) market size is dominated by thrombolytic therapeutics segment. This segment holds the major market share as thrombolysis is the only approved medical treatment for AIS, provided it is administered within a narrow time window. Among thrombolytic therapeutics, tissue plasminogen activator (tPA) is the most commonly administered drug for treating AIS given its ability to dissolve the blood clots causing ischemia.

Key Takeaways
The global Acute Ischemic Stroke (AIS) market is expected to witness high growth over the forecast period of 2023 to 2030. With advancements in acute stroke diagnosis and treatment and rising geriatric population susceptible to strokes, the market is set to grow at a significant pace. The global Acute Ischemic Stroke (AIS) Market is estimated to be valued at US$ 9.2 billion in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030.

Regional analysis: The AIS market in North America currently dominates due to presence of advanced healthcare infrastructure and healthcare expenditure. However, Asia Pacific region is anticipated to witness the highest growth rate owing to growing markets in China and India and economic development in key countries leading to improved accessibility to diagnosis and treatment options.

Key players: Key players operating in the Acute Ischemic Stroke (AIS) market are Boehringer Ingelheim, Daiichi Sankyo Company, Johnson & Johnson, and Bayer. These players are focused on expanding their product portfolio by developing novel therapeutics to widen treatment windows and improving clinical outcomes for patients with AIS.

Get more insights on this topic: https://www.newsstatix.com/acute-ischemic-stroke-ais-market-share-and-opportunity-analysis-2023-2030/